Gotham Therapeutics is developing a novel drug class that targets the epitranscriptomics machinery to modulate gene expression and cellular processes. This approach aims to address diseases linked to dysregulated RNA modifications, providing a new therapeutic avenue for conditions currently lacking effective treatments.
Funding
$54M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases are linked to dysregulated RNA modifications, but effective treatments are lacking. Targeting the epitranscriptomics machinery to modulate gene expression and cellular processes represents a novel therapeutic avenue.
Solution
Gotham Therapeutics is developing a new class of therapeutics that target epitranscriptomic proteins, enzymes that modify RNA. By modulating RNA modifications, Gotham aims to control gene expression and cellular processes, offering a new approach to treating diseases caused by dysregulated RNA. Their focus is on creating treatments for conditions where current options are inadequate.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing novel treatments for diseases related to RNA dysregulation.
Features
- Targets epitranscriptomic proteins to modify RNA.
- Modulates gene expression and cellular processes.
- Addresses diseases linked to dysregulated RNA modifications.
- Provides a new therapeutic avenue for conditions currently lacking effective treatments.